Promoteur(s) :
H. Lee Moffitt Cancer Center and Research Institute
Recrutement : fermé
Centres participants
18
Dernière modification : 2025-11-25
DESCRIPTION DE L'ÉTUDE
Résumé de l'étude
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Source : Importé depuis le centre
RECRUTEMENT
Profil des participants
Sexe(s) des participants
ALL
Source : Importé depuis le centre
Condition médicale (spécialité visée)
Domaine de recherche
Donnée non disponible
Critères de sélection
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Arm A - First Strike
Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
Donnée non disponible
Inconnu
Arm B - Second Strike - Maintenance
Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
Donnée non disponible
Inconnu
Arm C - Adaptive Therapy
Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
Donnée non disponible
Inconnu
Arm - D Conventional Therapy
Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
Donnée non disponible
Inconnu
Arm A - First Strike
État du recrutement
unknown
Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
Arm B - Second Strike - Maintenance
État du recrutement
unknown
Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
Arm C - Adaptive Therapy
État du recrutement
unknown
Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
Arm - D Conventional Therapy
État du recrutement
unknown
Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
Données à jour depuis :
25 novembre 2025
SITES ET CONTACTS
Centre principal
university of alabama at birmingham comprehensive cancer center
BIRMINGHAM, ALABAMA, UNITED STATES
Recrutement local
—
FERMÉ
Aussi disponible à: DURHAM, (NORTH CAROLINA), DALLAS, (TEXAS), ST. PETERSBURG, (FLORIDA), THE BRONX, (NEW YORK), AURORA, (COLORADO), HARTFORD, (CONNECTICUT), MIAMI, (FLORIDA), TAMPA, (FLORIDA), BUFFALO, (NEW YORK), CHAPEL HILL, (NORTH CAROLINA), CHARLOTTE, (NORTH CAROLINA), ...
et 6 autres villes.
Dernière modification :
25 novembre 2025
Données à jour depuis :
10 mars
Origine des données :
clinicaltrials.gov
* Participants must have a new histologic diagnosis of rhabdomyosarcoma
* Participants must have FISH, PCR or other molecular confirmation of PAX/FOXO1 fusion per institutional standards
* Participants must have sufficient tissue (up to 10 unstained FFPE) for correlative testing
* All participants must have distant metastatic disease; either biopsy positive or PET avid extranodal or distant nodal lesions determined by the investigator to be metastatic disease. Patients with a single distant metastatic site that has been excised prior to study entry are eligible
* No prior systemic chemotherapy
* Participants enrolled to Arm B, maintenance, must be able to take oral cyclophosphamide. Note: enteral administration of cyclophosphamide is allowable.
* Males and females of reproductive potential may not participate unless they have agreed to the use of, at minimum, two methods of contraception during and after treatment or abstinence.
* Women of childbearing potential should adhere to contraception for a period of 4 months after completion of systematic chemotherapy administration
* Men who are sexually active with women of child bearing potential should adhere to contraception for a period of 4 months after completion of systematic chemotherapy administration
* All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.
Exclusion Criteria:
* Participants with regional lymph nodes as the only site of disease are not eligible. Distant nodal sites alone are eligible
* Participants who are receiving any other investigational agents for rhabdomyosarcoma are ineligible
* Participants must not be receiving any additional medicines being given for the specific purpose of treating cancer. Alternative medications including, but not limited to cannabis based products would not be a reason for exclusion
* Participants are ineligible if they have uncontrolled intercurrent illness including, but not limited to:
* ongoing or active infection not expected to resolve with current antibiotic plan
* cardiac arrhythmia
* psychiatric illness/social situations that would limit compliance with study requirements
* Patients who are pregnant or breastfeeding are not eligible because there is no available information regarding human fetal or teratogenic toxicities. Females of childbearing potential must have a negative serum or urine pregnancy test within 24 hours of starting protocol therapy.
* Participants who are considered unable to comply with the safety monitoring requirements of the study are not eligible
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Arm A - First Strike
Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
Donnée non disponible
Inconnu
Arm B - Second Strike - Maintenance
Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
Donnée non disponible
Inconnu
Arm C - Adaptive Therapy
Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
Donnée non disponible
Inconnu
Arm - D Conventional Therapy
Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
Donnée non disponible
Inconnu
Arm A - First Strike
État du recrutement
unknown
Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
Arm B - Second Strike - Maintenance
État du recrutement
unknown
Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
Arm C - Adaptive Therapy
État du recrutement
unknown
Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
Arm - D Conventional Therapy
État du recrutement
unknown
Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
Données à jour depuis :
25 novembre 2025
Description de l'étude
Description de l'étude
Résumé de l'étude
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
10
affichés
sur
18
centres
CAROLINAS MEDICAL CENTER, LEVINE CANCER INSTITUTE
Charlotte
NORTH CAROLINA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CHILDREN'S HOSPITAL OF COLORADO
Aurora
COLORADO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CONNECTICUT CHILDREN'S MEDICAL CENTER
Hartford
CONNECTICUT, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
DUKE CHILDREN'S HOSPITAL
Durham
NORTH CAROLINA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
JOHNS HOPKINS ALL CHILDREN'S HOSPITAL
St. petersburg
FLORIDA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
MOFFITT CANCER CENTER
Tampa
FLORIDA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
MONTEFIORE MEDICAL CANCER CENTER
The bronx
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
NATIONWIDE CHILDREN'S HOSPITAL
Columbus
OHIO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
PRIMARY CHILDREN'S MEDICAL CENTER/UTAH
Salt lake city
UTAH, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
ROSWELL PARK COMPREHENSIVE CANCER CENTER
Buffalo
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
Centres participants
Source d'information
Dernière modification :
25 novembre 2025
Données à jour depuis :
10 mars
Origine des données :
clinicaltrials.gov